PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

International Journal of Clinical Oncology 2026 Open access

Read full text

Authors: Noriomi Matsumura

DOI: 10.1007/s10147-026-02994-4

Cited by: 1

References: 4

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research Head and Neck Cancer Studies

References 4